Trial Details
Not recruitingBasic Information
| Clinical ID | c3390 |
|---|---|
| Identifier | NCT00040521 |
| Trial Title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients With Active Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Crohn Disease;Inflammatory Bowel Disease |
| Interventions | Drug: Recombinant Human Interleukin-11 (rhIL-11) |
Participant Information
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
|---|---|
| City | - |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |